Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.
October 12, 2023
Share
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million on August 18, 2023. In similar transaction Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million. Qingdao Laoshan District Finance Bureau and Qingdao State-owned Assets Supervision and Administration Commission, approved for Huilong Huaze to acquire 9,720,000 shares in Hangzhou TianMuShan from Yongxin Huarui.
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd on October 13, 2023.
Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.